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Abstract
Background: Bronchiolitis is the commonest respiratory infection in children less than 12 months and cause of
hospitalisation in infants under 6 months of age in Australasia. Unfortunately there is substantial variation in
management, despite high levels of supporting evidence. This paper reports on the process, strengths and
challenges of the hybrid approach used to develop the first Australasian management guideline relevant to the
local population.
Method: An adaption of the nine steps recommended by the National Health and Medical Research Council
(NHMRC) and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology
were utilised. Following establishment of the Guideline Development Committee (GDC), we identified the
population, intervention, comparator, outcomes and time of interest (PICOt) questions, undertook a systematic
literature search and graded the evidence and recommendations using the NHMRC and GRADE processes. Using
Nominal Group Techniques (NGT), consensus was sought in formulating the clinical practice recommendations and
practice points. Key health professional bodies were consulted to ensure relevance in the Australasian emergency
and ward settings.
Results: From 33 PICOT questions, clinical recommendations for practice that were deemed relevant to the
Australasian population were identified. Specific considerations for the management of Australian and New Zealand
indigenous infants in relation to the use of azithromycin and risk factors for more serious illness are included.
Using NGT, consensus demonstrated by a median Likert score > 8 for all recommendations was achieved. The
guideline presents clinical guidance, followed by the key recommendations and evidence review behind each
recommendation.
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Conclusion: Developing evidence-based clinical guidelines is a complex process with considerable challenges.
Challenges included having committee members located over two countries and five time zones, large volume of
literature and variation of member’s knowledge of grading of evidence and recommendations. The GRADE and
NHMRC processes provided a systematic and transparent approach ensuring a final structure including bedside
interface, and a descriptive summary of the evidence base and tables for each key statement. Involvement of
stakeholders who will ultimately be end-users as members of the GDC provided valuable knowledge. Lessons learnt
during this guideline development process provide valuable insight for those planning development of evidence-
based guidelines.
Keywords: Bronchiolitis, Guideline, Infant, Management, Respiratory, Viral infection, Baby, Paediatric, Child,
Emergency department, Hospital
Background
Bronchiolitis, the commonest lower respiratory tract in-
fection in children less than 12 months of age, is the
most frequent cause of hospitalisation in infants under
six months of age [1, 2] and can be a life-threatening ill-
ness of infancy. In Australia, approximately 13,500 chil-
dren are admitted to hospital with bronchiolitis each
year. Bronchiolitis accounted for 56% of all admissions
to Australian hospitals of infants aged less than one year
in 2000/01 [3]. Groups most disadvantaged in our soci-
ety are disproportionately affected by bronchiolitis; in
New Zealand between 2003 and 2007, the rate of bron-
chiolitis was four times greater in indigenous children
than European children (rate ratio (RR) 4.31; 95% confi-
dence interval (CI) 4.15–4.47) and was nearly five times
greater in those living in the most deprived quintile than
those in the least deprived quintile (RR 4.74; 95% CI
4.47–5.03) [4].
Bronchiolitis is caused by a viral infection, most
commonly respiratory syncytial virus and is charac-
terised by acute inflammation, oedema and necrosis
of epithelial cells lining small airways, increased
mucus production, and bronchospasm. Signs and
symptoms are typically rhinitis, tachypnoea, wheezing,
cough, crackles/inspiratory crepitations, use of
accessory muscles, and/or nasal flaring [5], all con-
tributing to respiratory distress, reduced oxygenation
and difficulty feeding [6]. The management consists
solely of supportive therapies such as supplemental
oxygen and fluid replacement [6, 7]. Despite this, sub-
stantial variation in practice patterns occurs [8]. Re-
sults of an audit of the records of more than 3000
children who were admitted to seven Australasian
hospitals with bronchiolitis, identified that ineffective
interventions and diagnostic tools (e.g. inhaled salbu-
tamol, inhaled epinephrine, oral glucocorticoids, chest
x-ray, antibiotics) were used at least once in 27% to
48% of children [9]. The strategy to reduce this het-
erogeneity and use of ineffective practices was to de-
velop an evidence based Australasian guideline for the
management of infants presenting to, and admitted
into, hospital with bronchiolitis.
Evidence based clinical practice guidelines translate
findings from health research into recommendations for
clinical practice [10]. Guidelines contain systematically
developed statements that help practitioners and patient
decision makers decide on appropriate health care for
specific clinical circumstances [11]. Further, guidelines
offer explicit recommendations for clinicians, influence
the beliefs of healthcare providers and practitioners ac-
customed to outdated practices, improve the consistency
of care, and provide authoritative recommendations that
reassure practitioners about the appropriateness of their
treatment plan. Evidence based guidelines clarify which
interventions are of proven benefit and document the
quality of the supporting data [12].
Although high quality international clinical practice
guidelines for children with bronchiolitis exist for practi-
tioners in the United States [13] and the United King-
dom [14], there are none for Australasian clinicians.
Furthermore, the available international guidelines are
not completely applicable to the Australasian population
or setting as they do not take into consideration the dif-
fering environmental factors, prevalence and variance of
respiratory diseases, the indigenous population risk or
the health service delivery model [15].
At present many Australasian tertiary children’s hospi-
tals and State Government departments have developed
and utilise their own local guidelines for the manage-
ment of bronchiolitis in their setting [16–19]. However,
the methodology behind each of these guidelines is of
low-quality with none utilising a systematic review of
the literature, formal evaluation of the evidence or trans-
parent consensus processes. There is heterogeneity be-
tween guidelines ensuing variation in practice,
practitioner confusion, and increased medical costs due
to inefficiency in patient management. For example, re-
quirements for virology testing and acceptable oxygen
saturation levels vary between existing local Australasian
guidelines, both of which can directly contribute to
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increased length of hospital stay, unnecessary investiga-
tions, interventions and/or hospitalisations highlight the
need for a single high-quality guideline.
An Australasian guideline for the management of
bronchiolitis has the potential to standardise care for in-
fants presenting with one of the most common condi-
tions for children admitted to hospital. A guideline can
enable professionals from different disciplines to come
to an agreement about treatment and devise a quality
framework against which practice can be measured, not
only for tertiary hospital care but smaller regional, rural
and remote health facilities. The development and im-
plementation of an evidence based guideline has the po-
tential to align practice standards across Australasia,
allowing benchmarking, and individual institutions to
focus on suitable implementation strategies for know-
ledge translation in the local context. With such stand-
ardisation there are expected health benefits as
hospitalisation remains the primary determinant of
health care expenditure in bronchiolitis [14]. A high-
quality Australasian bronchiolitis clinical practice guide-
line will provide an important step in closing the gap be-
tween current clinical practice and best available
evidence [10] and provide rigorously developed, valid
and applicable recommendations for achieving the best
possible outcomes [20].
Clinical guidelines can be developed by organisa-
tions, individuals, task forces or institutions that have
a common aim to identify the current best practice
based on the available research evidence in the wider
context of patient and clinician experience. Guidelines
are rarely based on research evidence alone, but gen-
erally also incorporate the consensus view of experts.
Rigor and transparency are required in the process
selected to develop consensus [21] and several ap-
proaches can be used. The three most commonly
used methods being Nominal Group Technique
(NGT), the Delphi survey, or a combination/hybrid
approach [22].
The NGT can involve approximately eight to twelve
people who identify the questions to be included in a
guideline, express their views in private, and then discuss
areas of disagreement. After the discussion the group
members again provide their views in private to the
steering committee or organisers who analyse the re-
sponses to achieve group consensus. This process allows
all group members the opportunity to express their
views, reduces the risk of misunderstandings whilst iden-
tifying the reasons for differences of opinion, and is a
structured, transparent, and replicable way of synthesis-
ing individual judgments [23].
A Delphi method involves two or more rounds of
postal or electronic questionnaires to obtain consensus or
expert opinion. This method allows involvement of a
larger and more geographically dispersed group of partici-
pants and avoids the risk of some individuals exercising
undue influence [24]. The anonymity is a positive feature
of the Delphi method in that participants do not meet
face-to-face and therefore can present and react to ideas
unbiased by the identity of others. However, a Delphi sur-
vey has limited opportunity for group discussion, clarifica-
tion and resolution of differences of opinion. The Delphi
method also has reduced reliability in comparison to the
NGT [25].
Hybrid approaches occur where a combination of
questionnaire and face-to-face meetings are utilised to
reach consensus. This method can allow for greater
inclusion of stakeholder viewpoints [26] but can still
support anonymised voting on specific predetermined
aspects of a clinical guideline. Further discussion can
then take place to reach consensus without individ-
uals having to declare their own preference, therefore
providing a safer environment for discussion [22].
A key determinant of an evidence based guideline is
the methodological approach used to assess the qual-
ity of the research reviewed. Assessment of quality
directly guides the strength of the final recommenda-
tions for practice. There are several internationally ac-
cepted approaches for assessing and grading quality
of evidence. Examples of these processes are the
Grading of Recommendations Assessment, Develop-
ment and Evaluation (GRADE), National Health and
Medical Research Council (NHMRC) Evaluation of
Evidence process, Strength of Recommendation Tax-
onomy (SORT) and the Scottish Intercollegiate Guide-
line Network (SIGN) [27]. Grading both the quality
of the evidence and the strength of the recommenda-
tions has benefits to health care. Users of the guide-
lines or practice recommendations need to know how
much confidence they can apply to the underlying
evidence and recommendations cited within a guide-
line, therefore a systematic and explicit approach for
review and judgment of the quality of evidence is re-
quired [28].
The GRADE method entails an assessment of the
quality of a body of evidence for each individual out-
come to a given clinical question, including consider-
ation of within-study risk of bias (methodological
quality), the directness of the evidence, heterogeneity,
the precision of effect estimates and the risk of publica-
tion bias [29]. The GRADE method is recognised inter-
nationally as a reliable process for reviewing the quality
of evidence and is a structured process for developing
and presenting summary of findings for systematic re-
views and guidelines. The process is transparent and in-
cludes comprehensive criteria for downgrading and
upgrading the quality of the evidence ratings for the de-
velopment of recommendations [29].
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The NHMRC Evaluation of Evidence process is
Australian and addresses the evidence to support clin-
ical questions such as those relating to interventions,
diagnosis, prognosis, aetiology and screening which
are specifically related to guideline development [30].
The NHMRC Evaluation of Evidence process includes
rating five key components of the ‘body of evidence’
that contribute to each recommendation. These com-
ponents are: the evidence base, including number and
type of studies; the level of evidence and quality of
studies (risk of bias); the consistency of the study re-
sults; the potential clinical impact of the proposed
recommendation; the generalisability of the body of
evidence to the target population and the applicability
of the body of evidence in relation to the Australian
healthcare context [10]. The development of the
NHMRC process was adapted from the SIGN,
GRADE and SORT processes to provide a system that
aligned and complemented the NHMRC evidence di-
mensions and documents, giving consistency and local
clarity of approach [31].
The SIGN process encompasses a system that main-
tains the link between the strength of the available evi-
dence and the grade of the recommendation. The levels
of evidence are based on study design and methodo-
logical quality of individual studies. Utilising the SIGN
process, after synthesis of the evidence base, the Guide-
line Development Committee must make a subjective
judgement on the recommendations. This judgement is
based on their clinical experience in addition to their
knowledge of the evidence base [27].
Shukla et al. [32] reviewed and evaluated over 51 evi-
dence grading systems, with the highest scoring instru-
ments being GRADE and SIGN. The GRADE and
NHMRC processes were selected for developing the
Australasian Bronchiolitis Guideline. The GRADE
process was selected as this is currently being used by
the World Health Organisation (WHO) and increasingly,
worldwide. Further, GRADE has several advantages over
other systems such as explicit definitions and sequential
judgements and consideration of health benefit versus
harm, burden and cost. A limitation identified by Schü-
nemann [28] was the complexity of the GRADE System
and the need for a detailed manual or software to sim-
plify the use of the system. Rationale for selecting the
NHMRC process includes this being an Australian
process, endorsed by the NHMRC who is Australia’s ex-
pert body for health and medical research and promotes
the development and maintenance of public and individ-
ual health standards [33]. The NHMRC process is a
transparent method to formulate and grade recommen-
dations. Further, in order to gain NHMRC approval,
Australian guideline developers must comply with
NHMRC standards.
This paper reports on the methodology utilised to de-
velop a specific guideline for Australasian clinical prac-
tice; assessment of evidence using the NHMRC and
GRADE processes along with a hybrid consensus ap-
proach to develop clinical recommendations in a final
clinical guideline for the management of bronchiolitis in
the Australasian setting. The strengths and challenges
encountered are presented.
Methods
A structured guideline development process was uti-
lised (see Fig. 1). The aim was to formulate an evi-
dence based, clinical practice guideline for infants
with bronchiolitis presenting to, and admitted into
Australasian hospitals. The scope was to examine the
evidence for the diagnosis and management for the
purpose of improving health outcomes. The guideline
addresses the emergency department (ED) and general
ward management of bronchiolitis, recognising that in
order to influence management for the majority of
patients who present to hospital with bronchiolitis,
these two areas are critical to in-hospital manage-
ment. The guideline specifically excluded management
in primary care and intensive care units. These exclu-
sions were because hospitalisation is the primary de-
terminant of health care expenditure for bronchiolitis
[14] and only a small proportion of patients admitted
Fig. 1 Guideline Development Process Summary
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to hospital with bronchiolitis require intensive care
management [34]. It is recognised that although the
guidelines exclude these two management settings the
principles of management and evidence addressed in
the guideline process are relevant to both settings.
The principal target group to utilise the guideline will
be staff of, and health systems supporting, Australasian
EDs and general paediatric wards. The guideline will be
structured as a useable clinical interface with bed-side
functionality, including flow diagrams and tables of key
points. A descriptive summary of the evidence base and
evidence based tables from the GRADE and NHMRC
evidence review processes will sit behind the useable
clinical interface in the final document.
A Guideline Advisory Group (GAG) was formed
which consisted of the project chief investigators;
three paediatric emergency physicians, one paediatri-
cian and the project coordinator. The role of this
group was to provide expert advice and contribute to
the guideline development process including construc-
tion of population, intervention, comparator, out-
comes and time of interest (PICOt) questions,
defining the guideline scope and target audience, and
oversight of the project.
Further, a multidisciplinary Guideline Development
Committee (GDC) which included the members of the
GAG, was convened in accordance with the NHMRC
recommendations for guideline development [10]. This
committee comprised of twenty-two individuals, includ-
ing; eight General Paediatricians, one Paediatric Respira-
tory Physician, eight Paediatric Emergency Medicine
Physicians, one Paediatric Intensive Care Physician, one
Paediatric Nurse Practitioner, two Paediatric Nurses, and
one Paediatric Emergency Nurse from a mixture of Aus-
tralian and New Zealand metropolitan and non-
metropolitan centres, (including representatives from six
of the eight Australian States and Territories). The Aus-
tralian and New Zealand Paediatric Societies were also
approached seeking their representation for the GDC.
This committee was established to review and synthesise
the evidence to prepare the evidence based guideline,
ensuring relevance to their specific speciality areas of
representation.
The GAG initially identified 26 key PICOt questions
and relevant topics to be included based on the
American Academy of Paediatrics (AAP) 2014 bron-
chiolitis statement [35]. A face-to-face meeting was
conducted with the GDC during which the guideline
method was agreed. At this meeting current state and
tertiary children’s hospitals bronchiolitis guidelines
were reviewed and the original PICOt questions for-
mulated by the GAG were refined and expanded to
33 key questions relevant to the management of
bronchiolitis (Table 1).
Search strategy
A systematic literature search for all 33 questions was
undertaken. The search strategy inclusion criteria
included:
 Population: infants under 24 months of age with
bronchiolitis.
 Interventions: diagnostic tests and investigations,
oxygen therapies, medications, rehydration, scoring
systems and others that met individual research
questions (Table 1)
 Comparators: no treatment as a control, standard
care or treatment as usual or an alternative
intervention; comparisons between different modes
of delivery, frequency, dose or duration of
interventions were included.
 Outcomes: length of stay, admission, readmission,
death.
 Time: 1 January 2000 to 17 December 2015. Given
the GAGs’ extensive experience and previous
knowledge of the field, a fifteen year search range
was thought to be appropriate, realising that sentinel
work that had occurred prior to this would have
been included in relevant Cochrane reviews and
other meta-analysis.
 Language: English language.
The complete search strategy is included as Additional
file 1.
Exclusion Criteria included publications of case re-
ports, commentaries, editorials and letters, and those of
infants with bronchiolitis obliterans.
The following electronic databases were searched:
Ovid Medline, Ovid Embase, PubMed, Cinahl
(EBSCO), Cochrane Library, Cochrane Database of
Systematic Reviews (CDSR) and Cochrane Central
Register of Controlled Trials (CENTRAL) for system-
atic reviews and randomised controlled trials (RCTs).
Where systematic reviews and RCTs were not found,
quasi-experimental and non-experimental observa-
tional studies (e.g. case control studies and cohort
studies) were retrieved. If a systematic review pub-
lished in the Cochrane Library was relevant to a
question, only systematic reviews and RCTs from the
year of, and years subsequent to, the documented
search date in the Cochrane systematic review were
included.
The study selection process was conducted in a three
step process:
Step 1 – One of five members of the GAG reviewed
the title and abstracts of the articles identified in the lit-
erature search. Articles that met the inclusion criteria
and were relevant to any of the 33 questions were
included.
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Table 1 Questions answered relevant to the management of bronchiolitis
Number Question
1 In infants presenting to hospital what factors in history and physical examination contribute to a differential diagnosis of bronchiolitis?
2 In infants presenting to hospital with bronchiolitis, what are the risk factors for admission or severe disease (e.g. prolonged length of
hospital stay, intensive care unit (ICU) admission, and death)?
3 In infants presenting to hospital or hospitalised with bronchiolitis, does performing a CXR beneficially change medical management or
clinically relevant end-points?
4 In infants presenting to hospital or hospitalised with bronchiolitis, does performing laboratory tests (blood and/or urine) beneficially
change medical management or clinically relevant end-points?
5 In infants presenting to hospital or hospitalised with bronchiolitis, does performing virological investigations beneficially change medical
management or clinically relevant end-points?
6 For infants presenting to hospital or hospitalised with bronchiolitis, does use of a bronchiolitis scoring system beneficially change medical
management or clinically relevant end-points?
7 For infants presenting to hospital or hospitalised with bronchiolitis, what criteria should be used for safe discharge?
8a. i) In infants presenting to hospital or hospitalised with bronchiolitis, does administration of Beta2 Agonists (nebulisation, aerosol, oral or IV)
improve clinically relevant end-points?
8a. ii) In older infants presenting to hospital or hospitalised with bronchiolitis, does administration of Beta2 Agonists (nebulisation, aerosol,
oral or IV) improve clinically relevant end-points?
8b. i) In infants presenting to hospital or hospitalised with bronchiolitis, with a personal or family history of atopy, does administration of Beta2
Agonists (nebulisation, aerosol, oral or IV) improve clinically relevant end-points?
8b. ii) In older infants presenting to hospital or hospitalised with bronchiolitis, with a second or subsequent episode/s of bronchiolitis or
wheeze, does administration of Beta2 Agonists (nebulisation, aerosol, oral or IV) improve clinically relevant end-points?
9 In infants presenting to hospital or hospitalised with bronchiolitis, does administration of adrenaline / epinephrine (nebulisation, IM or IV)
improve clinically relevant end-points?
10 In infants presenting to hospital or hospitalised with bronchiolitis, does administration of nebulised hypertonic saline improve clinically
relevant end-points?
11a. In infants presenting to hospital or hospitalised with bronchiolitis, does administration of systemic or local glucocorticoids (nebulisation,
oral, IM or IV) improve clinically relevant end-points?
11b. In infants presenting to hospital or hospitalised with bronchiolitis, with a positive response to Beta2 Agonists, does administration of
systemic or local glucocorticoids (nebulisation, oral, IM or IV) improve clinically relevant end-points?
11c. In infants presenting to hospital or hospitalised with bronchiolitis, does administration of the combination of systemic or local
glucocorticoids (nebulisation, oral, IM or IV) and adrenaline improve clinically relevant end-points?
12a. In infants presenting to hospital or hospitalised with bronchiolitis, does administration of supplemental oxygen improve clinically
relevant end-points?
12b. In infants presenting to hospital or hospitalised with bronchiolitis, what level of oxygen saturation should lead to commencement or
discontinuation of supplemental oxygen to improve clinically relevant end-points?
13. In infants hospitalised with bronchiolitis does continuous monitoring of pulse oximetry beneficially change medical management or
clinically relevant end-points?
14. In infants hospitalised with bronchiolitis does the use of heated humidified high flow oxygen, or air, via nasal cannula improve clinically
relevant end-points?
15. In infants hospitalised with bronchiolitis, does chest physiotherapy improve clinically relevant end-points?
16a. In infants hospitalised with bronchiolitis, does suctioning of the nose or nasopharynx improve clinically relevant end-points?
16b. In infants hospitalised with bronchiolitis, does deep suctioning in comparison to superficial suctioning beneficially improve clinically
relevant end-points?
17 In infants hospitalised with bronchiolitis, does the use of nasal saline drops improve clinically relevant end-points?
18. In infants hospitalised with bronchiolitis, does the use of bubble CPAP improve clinically relevant end-points?
19. In infants hospitalised with bronchiolitis, is provision of home oxygen a safe alternative for management?
20a. In infants presenting to hospital or hospitalised with bronchiolitis, does the use of antibiotic medication improve clinically relevant
end-points?
20b. In infants presenting to hospital or hospitalised with bronchiolitis, does the use azithromycin medication improve clinically relevant
end-points?
20c. In infants presenting to hospital or hospitalised with bronchiolitis, does the use of antibiotic medication in infants who are at risk of
developing bronchiectasis, improve clinically relevant end-points?
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Step 2 – Where screening by title and abstract was in-
sufficient to make a decision as to relevance, a copy of
the complete article was sourced and reviewed in order
to make a decision regarding possible relevance. If fur-
ther uncertainty existed regarding possible relevance the
article was reviewed by a second person. Where there
was disagreement between reviewers or uncertainty final
inclusion or exclusion was decided upon by the five per-
son GAG.
See Additional file 2 – Prisma Diagram [36].
Step 3 – Included articles were then divided into
groups according to each question for which they may
be relevant. Where an article was relevant to more than
one question, it was placed into each appropriate group.
Methodological assessment
Members of the GDC were divided into four working
groups according to expertise to allow more effective
interaction via teleconference. The 33 questions were di-
vided into areas of clinical similarities and allocated to a
single group. Each article that was potentially relevant to
an individual question was independently reviewed by
two members for quality and the level of evidence utilis-
ing both the GRADE [29] and NHMRC Evaluation of
Evidence process [30]. Any disagreements that arose be-
tween the two reviewers were resolved through discus-
sion with a third reviewer.
On completion of the evidence grading, recommenda-
tions were reviewed within working groups via teleconfer-
ence to be included in a draft guideline. In areas with a
poor evidence base, the working groups discussed the evi-
dence base and current clinical practice and made clinical
practice recommendations and practice points for a draft
guideline. Alongside evidence tables, summaries of evi-
dence were prepared for each question with review by the
working groups and the GDC. Where possible, the evi-
dence was based on systematic reviews and randomised
controlled trials. Where there was only low level, unsup-
ported evidence, clinical care statements outlining current
accepted practice points were included.
Draft evidence tables and recommendations were
shared electronically with all members of the GDC. A
face-to-face meeting was then conducted where each
recommendation was presented and all GDC members
given the opportunity to present their view without
interruption. Discussion ensued and any alterations were
made before GDC members were requested to vote. To
ascertain consensus from the multidisciplinary GDC,
NGT principles [37] were used. Voting was confidential
and conducted using a Likert scale (where 1–3 = dis-
agree, 4–6 = neutral and 7–9 = agreement) for each rec-
ommendation and practice point with consensus of
agreement set as a median score of 7 as reported by
Rolls and Elliott [38] for each recommendation. This
process led to a series of statements which were struc-
tured into a succinct document suitable for use at the
patient bedside.
A draft guideline was produced including flow dia-
grams of patient care for infants with bronchiolitis, and
highlighting key assessment and treatment points
throughout the patient journey from ED presentation to
ward admission, inpatient stay and discharge. The struc-
ture for the draft guideline was agreed by all members of
the GDC.
The final step was to undertake stakeholder/know-
ledge user consultation. Formal feedback was sought
from Australian and New Zealand professional medical
and nursing colleges (which included: Australian Paedi-
atric Society, New Zealand Paediatric Society, Australa-
sian College of Emergency Medicine (ACEM), Royal
Australasian College of Physicians (RACP), New Zealand
Emergency Medicine Network, Australian College of
Children and Young Peoples Nurses (ACCYPN), New
Zealand Nursing Council and Children’s Healthcare
Australasia (CHA), in addition to the clinical leads of
general paediatrics and ED’s at Australian and New Zea-
land tertiary paediatric hospitals and consumers (Royal
Children’s Hospital Family Advisory Committee). All
feedback was reviewed by the GAG and changes and
corrections were made if deemed appropriate. This
review was the final consultation between researchers
and clinicians (knowledge users) to ensure relevance of
the final guideline to the Australasian emergency and
paediatric ward setting.
Results
Utilising the GRADE and NRMRC processes for asses-
sing evidence and a hybrid NGT method to achieve
Table 1 Questions answered relevant to the management of bronchiolitis (Continued)
Number Question
21a. In infants presenting to hospital or hospitalised with bronchiolitis, does the use of non-oral hydration improve clinically relevant
end-points?
21b. In infants presenting to hospital or hospitalised with bronchiolitis, what forms of non-oral hydration improve clinically relevant
end-points
21c. In infants presenting to hospital or hospitalised with bronchiolitis, does limiting the volume of non-oral hydration impact on
clinical relevant end-points?
22 In infants presenting to hospital or hospitalised with bronchiolitis, do infection control practises improve clinically relevant end-points?
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consensus recommendations, an evidence based Austra-
lasian Guideline for the management of Bronchiolitis in
infants was developed. From the 33 PICOT questions,
clinical recommendations for practice that were deemed
relevant to the Australasian population were identified
and are included in the guideline. Specific considerations
for the management of Australian and New Zealand in-
digenous infants in relation to the use of azithromycin
and risk factors for more serious illness are included.
Utilising the NGT method to ascertain consensus
amongst the GDC (n = 20) resulted in achievement of a
median Likert score > 8 for all recommendations. The
guideline is presented in such a way that the important
clinical guidance is at the front, followed by the key rec-
ommendations and the evidence review behind each of
these recommendations.
Discussion
Developing evidence based clinical guidelines is a com-
plex process. While some aspects of the process were
relatively simple, other areas provided challenges. The
key issues were establishing and sustaining stakeholder
engagement, management of literature, utilising the
grading systems by novice users and management of
communication across 5 time zones.
Stakeholder engagement:
Early and ongoing consultation with stakeholders can be
a major contributing factor to the success of a guideline
development process [39]. Therefore, the GDC was
established seeking diversity of specialisation and ensur-
ing adequate opportunities for discussion and input. A
wide representation of clinical experts from rural, metro-
politan, secondary and tertiary paediatric hospitals, with
geographical representation across Australia and New
Zealand, were members of the GDC. Attracting repre-
sentation and members of the committee was relatively
easy, indicating that the development of an Australasian
Guideline for bronchiolitis was of interest and perceived
as important and timely to improve management for in-
fants presenting to hospital with bronchiolitis. The initial
face-to-face meeting enabled team introductions and
specific interest areas to be identified prior to dividing
the committee into smaller working groups where com-
munication was primarily via email and teleconference.
Despite challenges of geographical disparity, committee
members were motivated and had effective communica-
tion skills, both of which were necessary to maintain
momentum for achievement of the outputs required to
meet the timeline agreed upon for the guideline
development.
Given the engagement of stakeholders throughout the
project, we anticipate implementation relevant to needs
and widespread translation into practice [40].
Management of literature
Despite partnering with a librarian, the volume and
management of the literature was challenging. The lit-
erature search was conducted as one search encompass-
ing all of the questions due to the expected large volume
of articles which were relevant to more than one ques-
tion. Notwithstanding utilising one search for all ques-
tions, over 12,000 articles were identified. Of these 3813
were duplicates, resulting in a total of 8717 articles for
screening for eligibility. As a consequence, the initial re-
view of this number of articles was time consuming but
perceived as necessary to be undertaken by only the five
members of the Advisory Group to ensure consistency.
Getting the appropriate balance between the sensitivity
of the search and precision [41] in retrieving relative ar-
ticles was assisted by grouping the review questions into
one search and having strict search parameters. Use of a
reference management system (Endnote) was essential
to organise such a large library and aided greatly in the
sorting and sharing of articles between the Guideline
Development group members. Lack of familiarity with
using the software however, was initially problematic for
some members of the Advisory and Guideline Develop-
ment Groups.
Grading systems
A further challenge was the grading of evidence for each
question utilising the GRADE and NHMRC processes.
This was due to many of the GDC members having min-
imal experience formally using these processes. Defini-
tions for terminology relating to grading of
recommendations were provided to assist with the com-
plexity of the process. Pre-reading and education mate-
rials on the grading processes were provided and the
pairings of a researcher with a clinician were deliberately
undertaken to ensure shared expertise. Despite these
strategies, many found the process of grading research
articles unfamiliar echoing Schünemann et al. [28] expe-
riences. Providing training on the processes may have
been beneficial and could have been included at the ini-
tial face-to-face meeting of the GDC. This may have re-
duced the burden of explanation and teaching of these
processes by the Advisory Group. Accredited GRADE
training is now available locally and should be utilised.
The advantages of using the GRADE system however,
outweighed the difficulties encountered. Advantages in-
cluded consideration of the health benefits versus harms,
burdens and costs and the development of the evidence
profile and summary [28] for each question. This should
assist clinicians to decide whether to use the recommen-
dations of the guideline. In addition, the NHMRC
process not only reflects the risk of bias in the study de-
sign, but takes into consideration the consistency of
findings between studies, clinical impact, generalisability
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and applicability of the results to the local health care
setting [10]. Although there is overlap of the two pro-
cesses, the GRADE process provides a transparent ap-
proach which is utilised worldwide and the NHMRC
process represents the latest approach recommended by
the leading Australian health research body to support
the translation of health and medical research into Aus-
tralasian clinical practice [30]. Therefore, utilisation of
both processes ensures universal understanding and ac-
ceptance internationally whilst complying with the rec-
ommendations of the NHMRC at a national level.
Communication
Although much communication was done electronic-
ally via email, greater engagement and contribution
from the group was enabled by conducting face-to-
face meetings as these provided a forum for open dis-
cussion. The second face-to-face meeting not only
provided a forum for discussion, but members of the
GDC were given the opportunity to vote on the final
clinical recommendations and achieve consensus of
the recommendations. Utilising a NGT [37] to reach
consensus was effective. Each recommendation con-
tained a single focus requiring agreement or non-
agreement based on the evidence collated and pre-
sented to support the recommendation. The NGT
elicited a response from all members of the group
present, however did not allow a voice from those
unable to attend the face-to-face meeting. For the 33
questions, the range of the mean scores was 8.36–
9.80 on a 10 point Likert scale, demonstrating con-
sensus was achieved. The members unable to attend
were given the opportunity following the meeting to
respond via email, but they were not able to be in-
volved actively and only aware of the discussion
which occurred on the day by way of meeting mi-
nutes. The discussion that did result regarding each
recommendation was largely based on suggestions for
minor changes to the strength of the recommendation
e.g. low to very low, rather than the statement itself.
Despite the challenges of having the GDC members
located over two countries and five time zones, more
than 12,000 articles to manage and review and variable
knowledge base of evidence grading by reviewers, there
were many positive experiences such as networking, skill
and knowledge development and a sense of achievement
on completion of the guideline which may contribute to
the delivery of evidence based care.
Conclusion
Development of an Australasian bronchiolitis guideline
based on the NHMRC and GRADE processes was a
challenging but valuable project for Australasian health
providers, both medical and nursing, and health
consumers. Stakeholder engagement from the onset
through to completion was high, reflecting interest and
the need for such a document. Involvement of stake-
holders who ultimately will also be the end users, pro-
vided valuable clinical knowledge which was beneficial
throughout the development process and ultimately will
lead to greater likelihood of implementation of the end
product [40].
Development of an evidence based national or inter-
national guideline such as this results in logistical chal-
lenges that do not occur for locally produced single
institution guidelines such as geographical disparity of
the committee members. A variable knowledge base of
grading of evidence is a potential challenge that may be
present in all situations and can have a huge impact on
the process, both in relation to outcome and time. Rec-
ommendations for future guideline developers planning
to use this process include: anticipating and identifying
learning needs about grading processes and reference
management systems; frequent regular teleconferences
to maintain engagement and progress and if financially
viable, additional face-to-face meetings may allow in-
creased productivity over a shorter time period.
The final guideline structure consists of a useable clin-
ical interface for bed-side functionality (including flow di-
agrams and tables of key points) with a descriptive
summary of the evidence base and evidence tables
(NHMRC and GRADE) for each key statement. This clin-
ical practice guideline provides an opportunity to close
the gaps between current clinical practice and the best
available evidence. An implementation strategy incorpor-
ating a knowledge translation project is planned to be
conducted by the PREDICT network as the next step to-
wards consistent, evidence informed practice.
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